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Abstract
I In nt tr ro od du uc ct ti io on n: :   The aim of the study was to assess the clinical efficacy, safety, and
disease-modification effects of tramiprosate (homotaurine, ALZHEMEDTM) in
mild-to-moderate Alzheimer’s disease (AD). 
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   Double-blind, placebo-controlled, randomized trial in 
67 clinical centres across North America. Patients aged ≥ 50 years, with mild-to-
moderate AD (Mini-Mental State Examination score between 16 and 26) and on
stable doses of cholinesterase inhibitors, alone or with memantine. Intervention:
78-week treatment with placebo, tramiprosate 100 mg or tramiprosate 150 mg BID.
Measurements: Alzheimer Disease Assessment Scale – cognitive subscale (ADAS-
cog) and Clinical Dementia Rating – Sum of Boxes (CDR-SB) assessments were
performed at baseline and every 13 weeks. Baseline and 78-week magnetic
resonance imaging (MRI) hippocampus volume (HV) measurements were conducted
in a subgroup of patients. 
R Re es su ul lt ts s: :   A total of 1,052 patients were enrolled and 790 (75.1%) completed the
78-week trial. Patient discontinuation and reasons for withdrawal were similar
across groups. Planned analyses did not reveal statistically significant between-
group differences. Lack of adequate statistical validity of the planned analysis
models led to the development of revised predictive models. These adjusted
models showed a trend toward a treatment effect for ADAS-cog (P = 0.098) and
indicated significantly less HV loss for tramiprosate 100 mg (P = 0.035) and
150 mg (P = 0.009) compared to placebo. The incidence of adverse events was
similar across treatment groups. 
C Co on nc cl lu us si io on ns s: :   The primary planned analyses did not show a significant treatment
effect, but were confounded by unexplained variance. Post-hoc analyses showed
a significant treatment-related reduction in HV loss. However, there was only a trend
towards slowing of decline on the ADAS-cog and no slowing of decline on the CDR-
SB. These results must be interpreted in consideration of the limitations of clinical
and disease-modification outcome measures and their relationship, the heterogeneity
of the disease and the impact of confounding demographic and clinical variables. 
K Ke ey y   w wo or rd ds s: :   tramiprosate, Alzheimer’s disease, amyloid, disease-modification,
volumetric MRI.
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Introduction
Current therapies for Alzheimer’s disease (AD)
are symptomatic with limited impact on the
disease itself. Treatment that slows or stops
disease progression remains an unmet need.
Accumulation of the amyloid ʲ (Aʲ) peptide is
a pivotal process in the natural history of AD.
Amyloid ʲ is generated by enzymatic cleavage of
the  amyloid  precursor  protein  (APP)  with
subsequent formation of toxic Aʲ oligomers and
amyloid fibrils, which are ultimately deposited 
as plaques in the brain [1]. This process is hypo  -
thesized to induce neurotoxic events that lead 
to neurovascular uncoupling, synaptic dysfunc  -
tion and neuronal loss [2, 3]. Ensuing structural
damage in some brain areas such as the hip  -
pocampus, as revealed by magnetic resonance
imaging, may be associated with, or even precede,
clinical symptoms [3]. Interventions that protect
against  Aʲ-induced  neurotoxicity  may  have
therapeutic value for the treatment of AD [4].
Tramiprosate (homotaurine, ALZHEMEDTM) is
a small, orally-administered compound that binds
to soluble Aʲ and reduces amyloid aggregation and
subsequent deposition [5]. In vitro, tramiprosate
provides  neuroprotection  against  Aʲ-induced
neurotoxicity in neuronal and mouse organotypic
hippocampal cultures, and reverses Aʲ-induced
long-term  potentiation  (LTP)  inhibition  in  rat
hippocampus [6], in part, through activation of 
ʲ-aminobutyric acid A (GABA-A) receptors [7]. In
vivo,  tramiprosate  produced  dose-dependent
reductions of Aʲ in the brain of transgenic mice
(hAPP-TgCRND8) [6]. Clinical studies [8] showed
that tramiprosate was safe and tolerable. In mild-
to-moderate AD patients [8] tramiprosate also
reduced Aʲ42 levels in CSF. 
The objectives of the Alphase, Phase III, North-
American multi-centre, randomized, double-blind,
placebo-controlled study was to assess the clinical
efficacy, safety, and disease-modification effects of
tramiprosate in patients with mild-to-moderate AD. 
Material and methods
P Pa at ti ie en nt ts s
Participants (men and women ≥ 50 years) had
a diagnosis of probable AD (DSM-IV-TR [9] and
NINCDS-ADRDA [10]) and a Mini-Mental State
Examination (MMSE) [11] score between 16 and 26.
Laboratory assessments, electrocardiograms (ECG)
and CT/MRI results were compatible with probable
AD. Patients were required to be on a stable dose
of a cholinesterase inhibitor (ChEI) which may have
been combined with memantine, for a minimum 
of  four  months  prior  to  the  screening  visit. 
Stable doses (≥ 1 month prior to screening) of
anxiolytics, sedatives, hypnotics, antidepressants,
antipsychotics, anticonvulsants, oestrogens, statins,
and  vitamin  E  (≤ 2050  IU/day)  were  allowed.
Patients with any other causes of dementia were
excluded, as were those with a body mass index 
<  19  or  >  28,  a life  expectancy  <  2  years,  or
a clinically significant and uncontrolled medical
disease. The study protocol was approved by the
ethics review board of each site. Written informed
consent was obtained from each patient or legally
authorized representative prior to study entry. 
S St tu ud dy y   d de es si ig gn n
This was a randomized, double-blind, placebo-
controlled, parallel-group study conducted at 67
study centres across the United States and Canada.
Patients were randomized to tramiprosate 100 mg
BID, tramiprosate 150 mg BID, or placebo BID 
for 78 consecutive weeks, including an 8-week 
dose escalation phase. Treatment was allocated
according to a randomization list issued by an
independent biostatistician, using a computer
random number generator, and balanced to ensure
a ratio of 1 : 1 : 1 across groups. Study medication
consisted  of  modified-release  coated  tablets,
identical in external appearance and containing
50 mg of tramiprosate or placebo. All doses were
administered orally as three tablets.
P Pr ro oc ce ed du ur re e
Clinical  efficacy  measures  were  Alzheimer’s
Disease Assessment Scale-cognitive subscale (ADAS-
cog) [12], Clinical Dementia Rating-Sum of Boxes
(CDR-SB) [13], MMSE [11], Clinical Interview Based
Impression  of  Change-plus  caregiver  interview 
(CIBIC-plus) [14], Neuropsychiatric Inventory (NPI) [15],
and Disability Assessment of Dementia (DAD) [16]
scores. Disease-modification measures were volu  -
metric magnetic resonance imaging (vMRI) of the
hippocampus, whole brain and entorhinal cortex,
plasma/CSF/urine Aʲ, and CSF tau. Safety measures
included Adverse Event (AE) reporting (MedDRA 9.0),
vital signs, clinical laboratory parameters, ECG, and
physical examinations.
Clinical and safety assessments were conducted
at Baseline and Weeks 13, 26, 39, 52, 65 and 78. HV
was measured at Baseline and at Week 78 in
a subgroup of patients at 51 sites. The complete
description  of  HV  measurements  is  provided
elsewhere [17]. Briefly, centralized assessment 
of  HV  was  derived  from  a 1.5T  T1-weighted 
3-dimensional  volumetric  MR  sequence  (TR  =
10/2160/9.5 ms, TE = 6.8/3.9/4 ms, 192 × 256/192 ×
× 256/256 × 256 matrix, 260/260/258 mm FOV, flip
angle = 20°/10°/8°, slice thickness = 1.6/1.6/1.6 mm
for  GE/Siemens/Philips,  respectively).  HV  was
computed using a semi-automated atlas-based
warping method [18]. 
Tramiprosate in Alzheimer’s disease104 Arch Med Sci 1, February / 2011
S St ta at ti is st ti ic ca al l   a an na al ly ys se es s   
In this report, only the ADAS-cog, CDR-SB, and HV
results will be reported as they constituted the
primary clinical efficacy and disease-modification
endpoints. Primary clinical efficacy endpoints were
the changes from Baseline to Week 78 in ADAS-cog
and CDR-SB scores. Secondary efficacy endpoints
were the changes from Baseline to Weeks 13, 26, 39,
and 52 in ADAS-cog and CDR-SB. Primary disease-
modification endpoints were the changes from
Baseline to Week 78 in vMRI of the hippocampus. 
Sample size calculations were based on the
assumptions that after 78 weeks, patients on
placebo would decline by a mean (SD) of 10 (8.0)
points on the ADAS-cog and 3.0 (2.3) points on the
CDR-SB [19]. Assuming a 25% effect size, the study
was powered to detect a difference of 2.5 points on
the ADAS-cog and 0.75 point on the CDR-SB with
90%  power  at  a two-tailed  5%  significance.
Adjusting for an approximate 30% dropout rate, an
enrolment of 315 patients per group was planned.
For HV, sample size estimate was based on an
untreated mean (SD) 5.2% (2.5%) annual change in
HV [20-25]. In order to detect a 20% difference in
the HV change between active and placebo with
80% power, at a 5% two-tailed significance, and
assuming an approximate 30% patient disconti  -
nuation rate, 150 patients per group were to be
enrolled in this sub-study. 
P Pl la an nn ne ed d   m mo od de el ls s
Changes from Baseline in ADAS-cog and CDR-SB
scores were assessed using mixed-effect repeated-
measures analyses of covariance (ANCOVA). These
models  tested  for  the  main  effects  of  Group
(treatment arm), Visit (treatment duration) and
Group × Visit (G × V) interaction, adjusted for
Baseline values and Site as covariates. The G × V
interaction reflected between-group differences in
least-square (LS) mean changes over time. Between-
group differences were determined using planned
contrasts comparing each active treatment group
to placebo with respect to the changes in ADAS-cog
and CDR-SB from Baseline to Week 78 (primary
clinical outcome) and from Baseline to Weeks 13,
26, 39, 52, and 65 (secondary clinical outcomes).
Change in HV was calculated by subtracting the final
visit volume from the Baseline volume using the Last
Observation  Carried  Forward  approach  for
withdrawn patients. Differences in changes over
time in HV between treatment arms were evaluated
with an ANCOVA in which the dependent variable
was the change in HV over the 78 Weeks of the
study and the independent variables were treatment
group with three levels (tramiprosate 150 mg BID,
tramiprosate 100 mg BID, and Placebo BID), duration
of follow-up (in months), Baseline HV and Site.
Between-group differences in the change in HV were
assessed with the overall F-test for treatment group
while differences between each active group and
placebo were assessed using planned contrasts.
A Ad dj ju us st te ed d   m mo od de el ls s
For all study outcomes, unanticipated and highly
significant Site effects (P < 0.001) were detected in
the planned ANCOVA models. This suggested that
either a significant amount of the variability was due
to differences between sites, or that “Site” was
concealing confounding variables that were not
accounted for in the model, contributing to poor
model fit. Post-hoc analyses aimed at reducing Site
effects and improving model fits were conducted.
Adjusted mixed-effects multivariate models were
developed using aggregate data. Additional covaria  -
tes  were  selected  using  a four-step  process: 
1) identification of cross-sectional and longitudinal
patterns in the data, 2) identification of variables
which  were  predictors  of  outcome  based  on
a statistical trend defined as a P < 0.15, 3) selection
of  variables  that  were  significant  independent
predictors of outcome, with a P < 0.15 tolerance, and
4)  assessment  of  the  clinical  relevance  of  the
identified variables by an independent scientific
advisory committee. The fixed effect covariates in the
planned models were removed based on likelihood
ratio test and information criteria improvement
(Akaike and Bayesian). Once the final adjusted models
were developed, treatment variables were included
in  a three-level  linear  mixed-effect  model  with
random site-specific intercepts and slopes for ADAS-
cog and CDR-SB, and a two-level linear mixed model
with random site-specific intercepts for HV. In the
adjusted models, contrasts comparing each active
group to Placebo at each visit were exploratory and
aimed  at  documenting  possible  trends.  No
adjustments for multiple comparisons were thus
required. Statistical trends (P < 0.15) are reported.
Both planned and adjusted models were based
on  observed  cases.  Efficacy  analyses  were
conducted in the Intent-to-Treat (ITT) population,
defined as all treated patients who had a Baseline
ADAS-cog or CDR-SB assessment and at least one
corresponding post-Baseline assessment. Disease-
modification analyses were based on the MRI-ITT
population, defined as ITT patients with a Baseline
and on-treatment MRI that was valid for evaluating
at least one of the targeted brain structures. Sites
that recruited fewer than six patients were pooled.
Twelve patients were excluded due to GCP non-
compliance. Statistical analyses were performed
using SAS version 9.12. 
Results
Patient disposition and baseline characteristics.
The study took place between August 2004 and
February  2007.  A total  of  1,432  patients  were
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screened, of whom 1,052 were randomized (placebo
BID: n = 353, tramiprosate 100 mg BID: n = 352,
tramiprosate 150 mg BID: n = 347) and 790 (75.1%)
completed the trial. Patient discontinuation and
reasons for withdrawal were similar across groups.
Adverse event (48.1%) and withdrawal of consent
(30.5%) were the most frequent reasons for early
discontinuation. Patient disposition is presented in
Figure  1.  There  were  no  statistical  differences
between groups with regards to baseline and
demographic characteristics (Table I). 
P Pl la an nn ne ed d   a an na al ly ys se es s
Table II summarizes results using the planned
analyses. All three groups experienced an increase
from  Baseline  to  each  visit  in  clinical  scores,
indicating deterioration. The planned ANCOVA
model for ADAS-cog did not reveal a significant G
× V  interaction  (P =  0.152)  although  planned
contrast  for  the  primary  ADAS-cog  outcome
revealed numerically less decline at Week 78 in the
100 mg versus placebo (–0.70 points). Neither the
planned G × V interaction (P = 0.573) nor the
planned contrast for the primary CDR-SB outcome
at Week 78 (100 mg vs. Placebo: P = 0.405; 150 mg
vs. Placebo: P = 0.837) revealed a statistically
significant treatment effect. Planned contrasts for
the secondary ADAS-cog outcomes revealed that,
relative  to  placebo,  the  100  mg  BID  group 
had a statistically lower change from Baseline 
(P = 0.027) at Week 26. No statistical difference
relative to placebo was observed for any of the
secondary CDR-SB outcomes. For HV change, the
planned model showed a non-significant treatment
effect (P = 0.120). Compared to Placebo, the 100 mg
BID group showed no volume change difference 
(P =  0.782),  while  a trend  toward  greater  HV
decrease was observed in the 150 mg BID group 
(P = 0.056).
A Ad dj ju us st te ed d   m mo od de el ls s
The adjusted models (Table III) improved data fit
as indicated by Aikaike Information Criteria (AIC)
values of 28772.5 for the ADAS-cog and 17355.4 for
MMSE – mini-mental state exam, LTFU – lost to follow-up, GDS – Geriatric Depression Scale, BMI – body mass index
F Fi ig gu ur re e   1 1. . Patient disposition
N = 1432
Patients screened
N = 1052
Patients randomized
N = 353
Placebo
BID
N = 352
Tramiprosate
100 mg BID
N = 347
Tramiprosate
150 mg BID
Adverse event (n = 38)
Lack of efficacy (n = 5)
Protocol violation (n = 2)
Lost to follow-up (n = 5)
Withdrawn consent (n = 19)
Other (n = 11)
Death (n = 0)
Adverse event (n = 46)
Lack of efficacy (n = 7)
Protocol violation (n = 0)
Lost to follow-up (n = 2)
Withdrawn consent (n = 30)
Other (n = 5)
Death (n = 1)
Adverse event (n = 42)
Lack of efficacy (n = 3)
Protocol violation (n = 2)
Lost to follow-up (n = 2)
Withdrawn consent (n = 31)
Other (n = 10)
Death (n = 1)
N = 380 Screen failures
Abnormal screening lab (n = 72)
MMSE < (n = 70)
Other (n = 61)
Withdrawn consent or LTFU in screening (n = 42)
MMSE > 26 (n = 37)
Clinically significant ECG findings (n = 27)
Exclusionary prior medication regimen (n = 25)
GDS > 10 (n = 17)
Multiple infarcts MRI/CT (n = 16)
MRI/CT inconsistent with AD (n = 8)
BMI < 19 (n = 5)
Completed
n = 273
Discontinued
n = 80
Completed
n = 261
Discontinued
n = 91
Completed
n = 256
Discontinued
n = 91
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the CDR-SB, compared to 31559.2 and 20030.3,
respectively, for the planned models. The ADAS-cog
adjusted  model  revealed  a statistical  trend  for
treatment effect in favour of the two tramiprosate
groups (G × V interaction: P = 0.098) while post-hoc
planned contrasts showed lower changes from
Baseline relative to placebo in the 100 mg BID group
at Week 26 (P = 0.065) and Week 52 (P = 0.090). The
adjusted model for CDR-SB revealed no significant
treatment effect (G × V interaction: P = 0.505). 
For HV, the adjusted model showed an improved
AIC of 3600.3 compared to 8139.1 for the planned
model. The following covariates and covariate
interactions were retained: Antidepressant Use,
Vitamin E Use, Genotype, Cardiovascular Disease,
Race, Type of ChEI Used, Total Intracranial Volume,
Whole  Brain  Volume  at  Baseline,  Baseline
Hippocampus Volume × Treatment, Age Group ×
× Treatment,  Genotype  × Treatment,  Race  ×
× Treatment,  Month  × Genotype,  Month  ×
× Cardiovascular  Disease,  Month  × Race,  and 
Month × Total Intracranial Volume. The HV adjusted
model  showed  a significant  treatment  effect 
(P = 0.011). Least square estimates of the mean
[95% CI] changes from Baseline were significantly
different from zero for the placebo (–419.3 mm3
[–642.1 to –196.4 mm3]; P < 0.001) and 100 mg BID
(–135.1 mm3 [–249.5 to –20.7 mm3]; P = 0.021)
groups, while the change of 79.5 mm3 (–182.5 to
341.5 mm3) observed for the 150 mg BID group was
not  (P =  0.550).  The  decrease  in  HV  were
significantly less than placebo for both the 100 mg
(P = 0.035) and 150 mg (P = 0.009) BID groups.
S Sa af fe et ty y
Table IV summarizes the most common adverse
events (AE) and serious adverse events (SAE) of all
causalities. The proportion of patients experiencing
at least one AE for the placebo, 100 mg BID and
150 mg BID groups was 92.1%, 95.2% and 94.8%,
respectively. Nausea, syncope, vomiting, and weight
decrease appeared to be dose-related. However,
the incidence of these AEs in the 100 mg BID group
was not statistically different from placebo. A total
of 255 patients (24.2%) experienced at least one
SAE with an incidence of 26.1%, 23.6% and 23.1%,
for the placebo, 100 mg and 150 mg BID groups,
respectively. Syncope and pneumonia were among
SAEs that appeared to be dose-related. Thirty-two
(3.0%) patients experienced an AE which resulted
in death. Mortality rate was higher in the placebo
group (4.0%) compared to the 100 mg (2.8%) and
150  mg  (2.3%)  BID  groups.  Gastrointestinal
disorders were among the most frequent AEs that
led to discontinuation, with a total of 38 (3.6%)
patients. When examining the AE profile among the
most  frequently  occurring  AEs  that  led  to
discontinuation, nausea (Placebo: 1 [0.3%]; 100 mg
BID: 3 [0.9%]; 150 mg BID: 10 [2.9%]) and vomiting
(Placebo: 0 [0%]; 100 mg BID: 4 [1.1%]; 150 mg BID:
7 [2.2%]) appeared to be dose-dependent events.
Laboratory test results were generally un  remar  -
kable, with no apparent clinical differences between
groups. 
Discussion
In this trial of tramiprosate in mild-to-moderate
AD, the planned analyses did not show statistically
significant between-group differences. Significant
Site effects and the impact of variables not included
in the planned analyses reduced model fit and
validity. In addition, reduced power due to within-
and  between-patient  variance,  as  well  as  the
unexpected low deterioration in the placebo group,
render these analyses inconclusive. Results of the
P Pl la ac ce eb bo o   B BI ID D 1 10 00 0   m mg g   B BI ID D 1 15 50 0   m mg g   B BI ID D A Al ll l   p pa at ti ie en nt ts s
( (N N = =   3 34 41 1) ) ( (N N = =   3 33 35 5) ) ( (N N = =   3 32 29 9) ) ( (N N = =   1 10 00 05 5) )
Race, Caucasian, n (%)  333 (97.7) 321 (95.8) 318 (96.7) 972 (96.7)
Sex, female, n (%)  182 (53.4) 167 (49.9) 184 (55.9) 533 (53.0)
Age [years], mean (range)  74.2 (51-92) 73.8 (50-92) 73.6 (48-94) 73.9 (48-94)
Education [years], mean (range)  14.1 (0-25) 13.9 (0-25) 14.1 (0-25) 14 (0-25)
1APOE4 genotype, at least 1 ʵ4 allele, n (%) 220 (64.7) 201 (58.6) 206 (60.6) 627(61.3)
2ChEI use [months], mean (range) 23.4 (0.6-125.1) 23.5 (1.3-101.3) 23.1 (1.9-117.9) 23.3 (0.6-125.1)
2Memantine use [months], mean (range) 12.8 (1.5-67.1) 12.4 (1.0-34.1) 11.6 (0.9-42.4) 12.3 (0.9-67.1)
ADAS-cog, mean (range)  22.2 (5.0-52.0) 22.1 (7.7-52.7) 21.7(4.0-48.0) 22.0 (4.0-52.7)
CDR-SB, mean (range)  5.8 (0.5-17.0) 5.7 (0.5-17.0) 5.7 (0.5-14.0) 5.7 (0.5-17.0)
MMSE, mean (range)  21.0 (12.0-26.0) 21.1 (15.0-26.0) 21.1 (15.0-26.0) 21.1 (12.0-26.0)
1all-enrolled population, 2at randomization, ChEI – cholinesterase inhibitors, comparisons against Placebo based on one-way ANOVAs (continuous
variables) and Cochran-Mantel-Haenszel (CMH) tests for general association (categorical variables) 
T Ta ab bl le e   I I. .   Demographic and baseline characteristics – ITT population
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Tramiprosate in Alzheimer’s disease
adjusted models, which improved
statistical fit and reduced the impact
of Site effects, revealed a statistical
trend toward a treatment effect on
cognition and a treatment-related
reduction in HV loss. Overall, tra  -
miprosate was well tolerated.
AD typically progresses from mild
functional  impairment  to  total
dependence and death over a period
of 5-20 years. A disease-modifying
treatment initiated in the mild stage
that slows progression by 25% would
be expected to have a significant
clinical impact. Consistent with this
goal,  and  based  on  results  from
earlier trials, our study was powered
to demonstrate a 2.5 point treatment
effect on the ADAS-cog at 18 months.
Although  we  had  estimated  an
approximate 10-point deterioration in
the placebo group, the 18-month non-
adjusted and adjusted changes in
ADAS-cog were only 7.4 points and
6.2 points, respectively. Accordingly,
a 25% difference from placebo would
be  equivalent  to  an  unadjusted
change of 1.8 points and an adjusted
change of 1.6 points. This trial was
thus  underpowered  to  detect
a treatment effect, an issue of im  -
portance to other disease-modifying
drug development programmes. 
Statistical powering may also be
affected by variance in longitudinal
outcome  measures  that  could
obscure potential treatment signals
and  bias  results  toward  the  null
hypothesis. In AD, many factors, such
as concomitant medication type and
dose, can affect outcome variability
and  their  combined  impact  likely
increases as trials become longer and
involve  larger  cohorts.  Simple
ANCOVA models, such as those used
in the planned analyses, may not
have  been  sufficient  to  model
unexplained variance arising from
uncontrolled conditions. Indeed, the
high unexplained variance found in
the planned statistical models was
the impetus for the development of
more complex mixed-effects models
that included multiple covariates and
yielded improvement in modelling fit.
This underscores the complexity of
AD and the importance of careful
consideration of statistical modelling108 Arch Med Sci 1, February / 2011
aimed at improving statistical fit and validity of
results.  
Results  of  the  HV  analysis  illustrate  the
importance of statistical modelling. Our planned
analysis showed a trend toward greater HV loss in
the 150 mg BID tramiprosate group, a finding
consistent with the AN-1792 amyloid vaccine trial,
which showed a non-significantly greater HV loss
in  the  antibody  responders  [26].  While  the
underlying neurological basis of the HV loss in the
V Vi is si it t   / /   p pa ar ra am me et te er r A AD DA AS S- -C Co og g C CD DR R- -S SB B
P Pl la ac ce eb bo o   B BI ID D 1 10 00 0   m mg g   B BI ID D 1 15 50 0   m mg g   B BI ID D P Pl la ac ce eb bo o   B BI ID D 1 10 00 0   m mg g   B BI ID D 1 15 50 0   m mg g   B BI ID D
( (N N = =   3 34 41 1) ) ( (N N = =   3 33 35 5) ) ( (N N = =   3 32 29 9) ) ( (N N = =   3 34 41 1) ) ( (N N = =   3 33 35 5) ) ( (N N = =   3 32 29 9) )
B Ba as se el li in ne e/ /n n 331 325 318 336 327 320
Mean (SD) 22.2 (8.3) 22.1 (8.6) 21.7 (8.3) 5.8 (2.8) 5.7 (2.6) 5.7 (2.5)
W We ee ek k   1 13 3/ /n n 297 295 293 302 299 295
LS mean change –1.6 –1.2 –1.5 0.2 0.4 0.2
95% CI –3.2;-0.0 –2.8-0.4 –3.0-0.1 –0.2-0.7 –0.1-0.8 –0.3-0.6
Difference (%) vs. placebo  0.4 (–25.0) 0.1 (–6.3) 0.2 (100.0) 0.0 (0.0)
P-value  0.302 0.761 0.314 0.656
W We ee ek k   2 26 6/ /n n 294 277 277 296 281 276
LS mean change –0.2 –1.0 –0.7 0.8 0.7 0.6
95% CI –1.8-1.4 –2.6-0.6 –2.3-0.9 0.3-1.2 0.3-1.2 0.2-1.1
Difference (%) vs. placebo  –0.8 (400.0) –0.5 (250.0) –0.1 (–12.5) –0.2 (–25.0)
P-value  0.065 0.223 0.703 0.276
W We ee ek k   3 39 9/ /n n 265 264 264 268 266 265
LS mean change 1.0 0.7 0.9 1.2 1.2 1.0
95% CI –0.7-2.7 –1.0-2.4 –0.8-2.6 0.7-1.7 0.7-1.7 0.5-1.5
Difference (%) vs. placebo  –0.3 (–30.0) –0.1 (–10.0) –0.0 (0.0) –0.2 (–16.7)
P-value  0.525 0.845 0.721 0.329
W We ee ek k   5 52 2/ /n n 260 259 251 261 258 250
LS mean change 3.1 2.0 2.3 2.0 1.8 1.7
95% CI 1.4-4.8 0.4-3.7 0.6-4.0 1.5-2.5 1.3-2.3 1.2-2.2
Difference (%) vs. placebo  –1.1 (–35.5) –0.8 (–25.8) –0.2 (–10.0) –0.3 (–15.0)
P-value  0.090 0.193 0.335 0.136
W We ee ek k   6 65 5/ /n n 246 243 236 247 244 237
LS mean change 4.5 3.8 4.2 2.5 2.3 2.3
95% CI 2.8-6.3 2.1-5.5 2.5-5.9 2.0-3.0 1.8-2.8 1.8-2.8
Difference (%) vs. placebo  –0.7 (–15.6) –0.3 (–6.7) –0.2 (–8.0) –0.2 (–8.0)
P-value  0.217 0.535 0.280 0.378
W We ee ek k   7 78 8/ /n n 248 242 229 245 243 233
LS mean change 6.2 5.4 6.3 3.0 2.7 3.0
95% CI 4.5-7.9 3.6-7.1 4.6-8.0 2.5-3.5 2.2-3.2 2.5;3.5
Difference (%) vs. placebo –0.8 (–12.9) 0.1 (1.6) –0.3 (–10.0) 0.0 (0.0)
P-value  0.174 0.873 0.232 0.915
Higher scores on ADAS-cog and CDR-SB indicate greater impairment and LS mean changes from Baseline > 0 indicate deterioration. The following
covariates and covariate interactions were retained in the adjusted ANCOVA Models. ADAS-cog: Race, Type of ChEI Used, Age (quartiles), Disease
Severity, Vitamin E dose, Antidepressant Use, Genotype, Visit X Disease Severity, Visit X Age (quartiles), and Visit X Memantine Dose. CDR-SB:
Cardiovascular Disease, Type of ChEI Used, Disease Severity, Memantine Use, Years of Education (quartiles), Antidepressant Use, Genotype,
Vitamin E Use, and Visit X Disease Severity
T Ta ab bl le e   I II II I. . Change in ADAS-cog and CDR-SB (Adjusted Models) – ITT population
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vaccine trial remains unclear, inclusion of covariates
selected on the basis of clinical relevance and
statistical significance in our trial reversed the
direction of the between-group difference, with no
change in HV in the 150 mg BID group and a lower
volume change relative to placebo in the 100 mg
BID  group.  Interestingly,  the  adjusted  model
identified  a significant  interaction  between
treatment and several covariates, specifically, age,
hippocampus  volume  at  baseline  and  APOE
genotype. These variables have previously been
found to exert an impact on HV in a number of
longitudinal imaging studies [27-29]. Our study
suggests that these variables may modulate the
effects of an anti-amyloid intervention on HV
changes over the course of the trial. Confirmation
of the impact of the above covariates and their
interaction with treatment in other data sets would
corroborate our findings and allow the development
of more complex imaging analysis plans in future
trials. 
In our study, we did not find close agreement
between  cognitive/clinical  and  HV  changes.
Psychometric tests and vMRI may not measure
precisely the same disease processes, and changes
in biological and cognitive measures may not occur
over the same time period [17, 30]. Nevertheless,
volumetric  MRI  and  cognitive  measures  are
complementary and may be implemented in AD
trials in order to document potential treatment
effects on the underlying disease and to provide
regulatory support for disease modification claims.
This trial is among the first published Phase III
trials of anti-amyloid compounds for the treatment
of  AD.  Planned  analyses  did  not  demonstrate
statistically significant between-group differences,
P Pr re ef fe er rr re ed d   t te er rm m   ( (P PT T) ) P Pl la ac ce eb bo o   B BI ID D   ( (N N = =   3 35 53 3) ) 1 10 00 0   m mg g   B BI ID D   ( (N N = =   3 35 52 2) ) 1 15 50 0   m mg g   B BI ID D   ( (N N = =   3 34 47 7) )
n n ( (% %) ) n n   ( (% %) ) n n   ( (% %) )
A Ad dv ve er rs se e   e ev ve en nt ts s
Fall 51 (14.4) 58 (16.5) 45 (13.0)
Depression 43 (12.2) 29 (8.2) 33 (9.5)
Nausea 42 (11.9) 58 (16.5) 75 (21.6)
Diarrhoea 41 (11.6) 41 (11.6) 49 (14.1)
Dizziness 39 (11.0) 50 (14.2) 38 (11.0)
Urinary tract infection 39 (11.0) 38 (10.8) 32 (9.2)
Upper respiratory tract infection 34 (9.6) 27 (7.7) 32 (9.2)
Agitation 31 (8.8) 34 (9.7) 26 (7.5)
Headache 29 (8.2) 25 (7.1) 28 (8.1)
Vomiting 28 (7.9) 33 (9.4) 47 (13.5)
Fatigue 25 (7.1) 26 (7.4) 23 (6.6)
Back Pain 25 (7.1) 23 (6.5) 23 (6.6)
Weight decrease 24 (6.8) 38 (10.8) 52 (15.0)
Insomnia 23 (6.5) 18 (5.1) 16 (4.6)
Cough 22 (6.2) 16 (4.5) 16 (4.6)
Nasopharyngitis 21 (5.9) 22 (6.3) 18 (5.2)
Anxiety 20 (5.7) 21 (6.0) 17 (4.9)
Syncope fainting 13 (3.7) 19 (5.4) 25 (7.2)
S Se er ri io ou us s   a ad dv ve er rs se e   e ev ve en nt ts s
Syncope 9 (2.5) 10 (2.9) 13 (3.8)
Congestive cardiac failure 7 (2.0) 4 (1.1) 1 (0.3)
Fall 4 (1.1) 5 (1.4) 1 (0.3)
Myocardial infarction 4 (1.1) 2 (0.6) 0 (0.0)
Pneumonia 2 (0.6) 4 (1.1) 8 (2.3)
MedDRA (Version 9.0) was used. PT presented in decreasing order of incidence in the placebo group. Patients are counted once per PT using the
most severe level for that event. For some PT, incidence may be derived from more than one System Organ Class
T Ta ab bl le e   I IV V. .Most common adverse events (> 5%) and serious adverse events (> 1%) in any treatment group, all causalities,
safety population
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but were confounded by weakness of the statistical
models.  Post-hoc  adjusted  analyses  showed
a treatment effect in reducing HV loss and a trend
toward reduced cognitive decline. These results
must  be  interpreted  in  consideration  of  the
limitations of the outcome measures, the hete  -
rogeneity of the disease and the impact of de  -
mographic, genetic and clinical variables on patient
outcome. 
Acknowledgments
The authors wish to thank all patients and their
families who took part in the trial. They also wish
to acknowledge the Alphase Investigators for their
contributions in conducting the study. From the
United States: Paul S. Aisen, Tom Ala, Stephen
Aronson, B. Ashok Raj, Roberta Ball, Jose De La
Gandara,  Steven T.  DeKosky,  Juan  Espinosa,
Robert G. Feldman, Steven Ferris, Stephen Flitman,
Jose Gamez, Gary Gerard, J. Goldstein, Norman
Gordon, Sanjay Gupta, Lindy Harrell, Mark Harris,
Richard Holub, James Kimball, Louis Kirby, Chandra
Krishnasastry, Alan Lerner, Jary Lesser, David Ira
Margolin, Jacobo E Mintzer, Leslie Moldauer, Eric
Pfeiffer, Nunzio Pomara, Anton Porsteinsson, Ralph
Richter, Joel Ross, Barry Rovner, Donald Royall, Carl
Sadowsky, Stephen Salloway, Frederick Schaerf, Fred
Sheftell, Ram Shrivastava, Bart Sloan, Paul Solomon,
Reisa Sperling, Mary Stedman, Susan J. Steen, Joel
Streim, Stephen Thein, Michael Tuchman, Larry
Tune, C. van Dyck, Richard Weisler. From Canada:
Peter Bailey, Michael Borrie, Remi W. Bouchard,
Howard Chertkow, Sharon Cohen, Angeles Garcia,
Serge Gauthier, Marcel Germain, Danilo Antonio
Guzman, Nathan Herrmann, David Hogan, Jack
Kooy, Chris MacKnight, Giovanni Marotta, Ziad
Nasreddine, Emmanuelle Pourcher, Alain Robillard.
References
1. Gandy S. The role of cerebral amyloid ʲ accumulation in
common forms of Alzheimer disease. J Clin Invest 2005;
115: 1121-9.
2. Canevari L, Abramov A, Duchen MR. Toxicity of amyloid
B peptide: tales of calcium, mitochondria, and oxidative
stress. Neurochem Res 2004; 29: 637-50.
3. Schaller BJ. Strategies for molecular imaging dementia
and neurodegenerative diseases. Neuropsychiatr Dis Treat
2008; 4: 585-612.
4. Citron M.  Strategies  for  disease  modification  in
Alzheimer’s disease. Nat Rev Neurosci 2004; 5: 677-85.
5. Gervais F, Paquette J, Morissette C, et al. Targeting soluble
Abeta peptide with Tramiprosate for the treatment of
brain amyloidosis. Neurobiol Aging 2007; 28: 537-47.
6. Krzywkowski  P,  Sebastiani  G,  Williams  S,  et  al.
Tramiprosate Prevents Amyloid Beta-induced Inhibition
of Long-term Potentiation in Rat Hippocampal Slices. 8th
International Conference AD/PD, Salzburg, Austria, March
14-18, 2007.
7. Azzi M, Morissette C, Fallon L, et al. Involvement of both
GABA-dependent and -independent pathways in trami  -
prosate neuroprotective effects against amyloid-beta
toxicity. 8th International Conference AD/PD, Salzburg,
Austria, March 14-18, 2007.
8. Aisen PS, Saumier D, Briand R, et al. A Phase II study
targeting amyloid-beta with 3APS in mild-to-moderate
Alzheimer disease. Neurology 2006; 67: 1757-63.
9. American  Psychiatric  Association.  Diagnostic  and
Statistical Manual of Mental Disorder, Fourth Edition, Text
Revision.  Washington,  DC:  American  Psychiatric
Association, 2000.
10. McKhann G, Drachman D, Folskein M, Katzman R, PriceD,
Stadlan EM. Clinical diagnosis of Alzheimer's disease:
report of the NINCDS-ADRDA Word Group under the
auspices of Department of Health and Human Services
Task Force on Alzheimer's Disease. Neurology 1984; 34:
939-44.
11. Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State”
a practical method for grading the cognitive state of
patients for the clinician. Psychiatr Res 1975; 12: 189-98.
12. Mohs RC, Cohen L. Alzheimer's Disease Assessment Scale
(ADAS). Psychopharmacol Bull 1988; 24: 627-8.
13. Morris JC. The Clinical Dementia Rating (CDR): current
version and scoring rules. Neurology 1993; 43: 2412-4.
14. Schneider  LS,  Olin  JT,  Doody  RS,  et  al.  Validity  and
Reliability of the Alzheimer’s Disease Cooperative Study-
Clinical Global Impression of Change. Alzheimer Dis Assoc
Disord 1997; 11 (Suppl. 2): S22-S32.
15. Cummings JL. The Neuropsychiatric inventory: assessing
psychopathology in dementia patients. Neurology 1997;
48: S10-S16.
16. Gélinas I, Gauthier L, McIntyre M, Gauthier S. Development
of a functional measure for persons with Alzheimer’s
disease: the disability assessment for dementia. Am 
J Occup Ther 1999; 53: 471-81.
17. Gauthier S, Aisen PS, Ferris SH, et al. Effect of tramiprosate
in patients with mild-to-moderate Alzheimer's disease:
exploratory analyses of the MRI sub-group of the Alphase
study. J Nutr Health Aging 2009; 13: 550-7.
18. Hsu YY, Schuff N, Du AT, et al, Comparison of automated
and manual MRI volumetry of hippocampus in normal
aging and dementia. J Magn Reson Imaging 2002; 16: 
305-10.
19. Aisen PS, Schafer KA, Grundman M, et al. Effects of
rofecoxib or naproxen vs. placebo on Alzheimer disease
progression: a randomized controlled trial. JAMA 2003;
289:2819-26.
20. Csernansky  JG,  Wang  L,  Joshi  S,  et  al.  Early  DAT  is
distinguished from aging by high-dimensional mapping
of the hippocampus. Neurology 2000; 55: 1636-43.
21. Dickerson BC, Goncharova I, Sullivan MP, et al. MRI-
derived entorhinal and hippocampal atrophy in incipient
and very mild Alzheimer’s disease. Neurobiol Aging 2001;
22: 747-54.
22. Du AT, Schuff N, Amend D, et al. Magnetic resonance
imaging of the entorhinal cortex and hippocampus in mild
cognitive impairment and Alzheimer’s disease. J Neurol
Neurosurg Psychiatry 2001; 71: 441-7.
23. Ezekiel F, Chao L, Kornak J, et al. Comparisons between
global and focal brain atrophy rates in normal aging and
Alzheimer’s disease. Alzheimer Dis Assoc Disord 2004;
18: 196-201.
24. Jack CR Jr, Petersen, RC, Xu Y, et al. Rates of hippocampal
atrophy correlate with change in clinical status in aging
and AD. Neurology 2000; 55: 484-90.
25. Jack  CR  Jr,  Slomkowski  M,  Gracon  S,  et  al.  MRI  as
a biomarker of disease progression in a therapeutic trial
of melameline for AD. Neurology 2003; 60: 253-60.
P .S. Aisen, S. Gauthier, S.H. Ferris, D. Saumier, D. Haine, D. Garceau, A. Duong, J. Suhy, J. Oh, W.C. Lau, J. Sampalis for the Alphase groupArch Med Sci 1, February / 2011 111
26. Fox NC, Black RS, Gilman, S, et al. Effects of Aʲimmunization
(AN1792) on MRI measures of cerebral volume in Alzheimer
disease. Neurology 2005; 64: 1563-72.
27. Hashimoto  M,  Kazui  H,  Matsumoto  K,  et  al.  Does
donepezil treatment slow the progression of hippocampal
atrophy  in  patients  with  Alzheimer's  disease?  Am 
J Psychiatry 2005; 162: 676-82.
28. Moffat SD, Szekely CA, Zonderman AB, et al. Longitudinal
change  in  hippocampal  volume  as  a function  of
apolipoprotein E genotype. Neurology 2000; 55: 134-6.
29. Mueller SG, Weiner MW. Selective effect of age, Apo e4,
and  Alzheimer's  disease  on  hippocampal  subfields.
Hippocampus 2009; 19: 558-64.
30. Saumier D, Aisen PS, Gauthier S, et al. Lessons learned
in the use of volumetric MRI in therapeutic trials in
Alzheimer's  disease:  the  ALZHEMED  (Tramiprosate)
experience. J Nutr Health Aging 2009; 13: 370-2.
Tramiprosate in Alzheimer’s disease